Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Study of VX-770 on Desipramine
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT01153542
- Locations
- 🇺🇸
Covance CRU, Inc., Daytona Beach, Florida, United States
Study of VX-985 in Subjects With Chronic Hepatitis C
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 21
- Registration Number
- NCT01144936
- Locations
- 🇺🇸
Kansas, Overland Park, Kansas, United States
🇺🇸Maryland, Baltimore, Maryland, United States
🇺🇸Washington, Tacoma, Washington, United States
Rollover Study of VX-770 in Cystic Fibrosis Subjects
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 192
- Registration Number
- NCT01117012
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 152
- Registration Number
- NCT01080222
Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2010-04-16
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT01060566
- Locations
- 🇺🇸
Covan CRU, Inc., Daytona Beach, Florida, United States
A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 206
- Registration Number
- NCT01052194
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 60
- Registration Number
- NCT01048255
- Locations
- 🇺🇸
Florida, Sarasota, Florida, United States
🇺🇸New York, New York, New York, United States
🇺🇸Missouri, Chesterfield, Missouri, United States
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2010-04-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 20
- Registration Number
- NCT01038167
Study of VX-770 and Rifampin in Healthy Male Subjects
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2010-05-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT01018368
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 62
- Registration Number
- NCT00983853
© Copyright 2024. All Rights Reserved by MedPath